Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Puma Biotechnology's Gains from Sales and Divestitures fell 987.03% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 987.03%. This contributed to the annual value of $1.4 million for FY2024, which is 720.93% up from last year.
  • Puma Biotechnology's Gains from Sales and Divestitures amounted to $1.2 million in Q3 2025, which was down 987.03% from $731009.0 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Gains from Sales and Divestitures registered a high of $1.4 million during Q4 2024, and its lowest value of $189625.0 during Q1 2022.
  • In the last 5 years, Puma Biotechnology's Gains from Sales and Divestitures had a median value of $774455.0 in 2021 and averaged $807027.2.
  • As far as peak fluctuations go, Puma Biotechnology's Gains from Sales and Divestitures skyrocketed by 10973.58% in 2021, and later tumbled by 2048.38% in 2022.
  • Quarter analysis of 5 years shows Puma Biotechnology's Gains from Sales and Divestitures stood at $1.1 million in 2021, then dropped by 6.55% to $1.0 million in 2022, then rose by 27.84% to $1.3 million in 2023, then increased by 7.21% to $1.4 million in 2024, then decreased by 12.36% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures was $1.2 million in Q3 2025, compared to $731009.0 in Q2 2025 and $509340.0 in Q1 2025.